Skip to main content

Physostigmine Pregnancy and Breastfeeding Warnings

Brand names: Anticholium, Antilirium

Medically reviewed by Drugs.com. Last updated on Aug 16, 2023.

Physostigmine Pregnancy Warnings

Benefit should outweigh risk.

AU TGA pregnancy category: C
US FDA pregnancy category: C

Animal studies data is not available. There are no controlled data in human pregnancy. This drug crosses the blood-brain barrier and would be expected to cross the placenta.

AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Physostigmine Breastfeeding Warnings

Benefit should outweigh risk.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments:
-Because of its low molecular weight, excretion into breast milk is probable.

See references

See also

References for pregnancy information

  1. Cerner Multum, Inc. "Australian Product Information."
  2. (2016) "Product Information. Physostigmine Salicylate (physostigmine)." Taylor Pharmaceuticals

References for breastfeeding information

  1. Cerner Multum, Inc. "Australian Product Information."
  2. (2016) "Product Information. Physostigmine Salicylate (physostigmine)." Taylor Pharmaceuticals

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer